New advances in focal therapy for early stage prostate cancer

References

• Ferlay J, Soerjomataram I, Ervik M, et al., GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2012. Available from http://globocan.iarc.fr/ ​
   Google Scholar
• Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425-1437. ​
   Google Scholar
• Tay KJ, Mendez M, Moul JW, et al. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? Curr Opin Urol. 2015;25(3):185–190.
   PubMed Web of Science ®Google Scholar
• Onik G, Vaughan D, Lotenfoe R, et al. “Male lumpectomy”: focal therapy for prostate cancer using cryoablation. Urology. 2007;70((6 Suppl)):16–21.
   PubMed Web of Science ®Google Scholar
• Catto JW, Robinson MC, Albertsen PC, et al. Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the protecT study. Br J Cancer. 2011;105(7):931–937.
   PubMed Web of Science ®Google Scholar
• Tay KJ, Polascik TJ. Focal cryotherapy for localized prostate cancer. Arch Esp Urol. 2016;69(6):317–326.
   PubMedGoogle Scholar
• Schulman AA, Tay KJ, Robertson CN, et al. High-intensity focused ultrasound for focal therapy: reality or pitfall? Curr Opin Urol. 2017;27(2):138–148.
   PubMed Web of Science ®Google Scholar
• Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361(17):1704–1706.
   PubMed Web of Science ®Google Scholar
• Ahmed HU, Dickinson L, Charman S, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol. 2015;68(6):927–936.
   PubMed Web of Science ®Google Scholar
• Tsivian M, Kimura M, Sun L, et al. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int. 2010;105(8):1089–1092.
   PubMed Web of Science ®Google Scholar
• Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate – a 4-year experience. Urology. 2007;70((6 Suppl)):27–35.
   PubMed Web of Science ®Google Scholar
• Onik G, Transperineal BW. 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol. 2008;26(5):506–510.
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Mayes JM, Schroeck FR, et al. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009;115(10):2104–2110.
   PubMed Web of Science ®Google Scholar
• Tsivian M, Abern MR, Qi P, et al. Short-term functional outcomes and complications associated with transperineal template prostate mapping biopsy. Urology. 2013;82(1):166–170.
   PubMed Web of Science ®Google Scholar
• Futterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045–1053.
   PubMed Web of Science ®Google Scholar
• Tay KJ, Gupta RT, Rastinehad AR, et al. Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. Expert Rev Anticancer Ther. 2016;16(3):303–311.
   PubMed Web of Science ®Google Scholar
• Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol. 2016;69(1):16–40.
   PubMed Web of Science ®Google Scholar
• Scheltema MJ, Tay KJ, Postema AW, et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol 35(5):695-701. ​
   Google Scholar
• Garcia-Reyes K, Passoni NM, Palmeri ML, et al. Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging. 2015;40(1):134–142.
   PubMed Web of Science ®Google Scholar
• Tay KJ, Gupta RT, Brown AF, et al. Defining the incremental utility of prostate multiparametric magnetic resonance imaging at standard and specialized read in predicting extracapsular extension of prostate cancer. Eur Urol. 2016;70(2):211–213.
   PubMed Web of Science ®Google Scholar
• Truong M, Hollenberg G, Weinberg E, et al. Impact of Gleason subtype on prostate cancer detection using multiparametric MRI: correlation with final histopathology. J Urol. 2017. [Epub ahead of print]. ​
   PubMedGoogle Scholar
• Priester A, Natarajan S, Khoshnoodi P, et al. Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology. J Urol. 2017;197(2):320–326.
   PubMed Web of Science ®Google Scholar
• Moldovan PC, van den Broeck T, Sylvester R, et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer guidelines panel. Eur Urol. 2017. [Epub ahead of print]. ​
   Web of Science ®Google Scholar
• Tay KJ, Scheltema MJ, Ahmed HU, et al. Patient selection for prostate focal therapy in the era of active surveillance: an international Delphi consensus project. Prostate Cancer Prostatic Dis. 2017. [Epub ahead of print]. ​
   Google Scholar
• Umbehr MH, Muntener M, Hany T, et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106–117.
   PubMed Web of Science ®Google Scholar
• Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226–235.
   PubMed Web of Science ®Google Scholar
• Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–697.
   PubMed Web of Science ®Google Scholar
• Rowe SP, Gage KL, Faraj SF, et al. (1, 8)F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56(7):1003–1010.
   PubMed Web of Science ®Google Scholar
• Eiber M, Nekolla SG, Maurer T, et al. (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging. 2015;40(6):1769–1771.
   PubMedGoogle Scholar
• Bonnal JL, Marien A, Rock A, et al. V49 - Trimodal (18) F-choline-PET/mpMRI/TRUS targeted prostate biopsies: first clinical experience. Eur Urol Supplements. 2017;16(3):e2102–e3.
   Google Scholar
• Boehm K, Salomon G, Beyer B, et al. Shear wave elastography for localization of prostate cancer lesions and assessment of elasticity thresholds: implications for targeted biopsies and active surveillance protocols. J Urol. 2015;193(3):794–800.
   PubMed Web of Science ®Google Scholar
• Palmeri ML, Glass TJ, Miller ZA, et al. Identifying clinically significant prostate cancers using 3-D in vivo acoustic radiation force impulse imaging with whole-mount histology validation. Ultrasound Med Biol. 2016;42(6):1251–1262.
   PubMed Web of Science ®Google Scholar
• Postema A, Mischi M, de la Rosette J, et al. Multiparametric ultrasound in the detection of prostate cancer: a systematic review. World J Urol. 2015;33(11):1651–1659.
   PubMed Web of Science ®Google Scholar
• Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–560.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095–1099.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–255.
   PubMed Web of Science ®Google Scholar
• Onik G, Vaughan D, Lotenfoe R, et al. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26(5):500–505.
   PubMed Web of Science ®Google Scholar
• Truesdale MD, Cheetham PJ, Hruby GW, et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J. 2010;16(5):544–549.
   PubMed Web of Science ®Google Scholar
• Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012;62(1):55–63.
   PubMed Web of Science ®Google Scholar
• Durand M, Barret E, Galiano M, et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int. 2014;113(1):56–64.
   PubMed Web of Science ®Google Scholar
• Lian H, Zhuang J, Yang R, et al. Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients. Int Urol Nephrol. 2016;48(1):85–90.
   PubMed Web of Science ®Google Scholar
• van Velthoven R, Aoun F, Marcelis Q, et al. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2016;19(1):79–83.
   PubMed Web of Science ®Google Scholar
• Feijoo ER, Sivaraman A, Barret E, et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. Eur Urol. 2016;69(2):214–220.
   PubMed Web of Science ®Google Scholar
• Mendez MH, Passoni NM, Pow-Sang J, et al. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. J Endourol. 2015;29(10):1193–1198.
   PubMed Web of Science ®Google Scholar
• Tay KJ, Polascik TJ, El-Shafei A, et al. Propensity score matched comparison of partial to whole gland cryotherapy for intermediate-risk prostate cancer: an analysis of the COLD registry data. J Endourol. 2017;31(6):564-571. ​
   Google Scholar
• Barqawi AB, Stoimenova D, Krughoff K, et al. Targeted focal therapy for the management of organ confined prostate cancer. J Urol. 2014;192(3):749–753.
   PubMed Web of Science ®Google Scholar
• Hale Z, Miyake M, Palacios DA, et al. Focal cryosurgical ablation of the prostate: a single institute’s perspective. BMC Urol. 2013;13:2.
   PubMed Web of Science ®Google Scholar
• Valerio M, Shah TT, Shah P, et al. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: a prospective development study. Urol Oncol. 2017;35(4):150.e1-150.e7.
   PubMed Web of Science ®Google Scholar
• Tay KJ, Chen K, Law YM, et al. Early outcomes of combination MRI-targeted and saturation trans-perineal biopsy in restaging low-risk prostate cancer for active surveillance (MP48-08). J Urol. 2015;193(4):e597.
   Web of Science ®Google Scholar
• Burtnyk M, Hill T, Cadieux-Pitre H, et al. Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup. J Urol. 2015;193(5):1669–1675.
   PubMed Web of Science ®Google Scholar
• Ramsay E, Mougenot C, Staruch R, et al. Evaluation of focal ablation of magnetic resonance imaging defined prostate cancer using magnetic resonance imaging controlled transurethral ultrasound therapy with prostatectomy as the reference standard. J Urol. 2017;197(1):255–261.
   PubMed Web of Science ®Google Scholar
• Oto A, Sethi I, Karczmar G, et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013;267(3):932–940.
   PubMed Web of Science ®Google Scholar
• Eggener SE, Yousuf A, Watson S, et al. Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer. J Urol. 2016;196(6):1670–1675.
   PubMed Web of Science ®Google Scholar
• Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6(4):295–300.
   PubMed Web of Science ®Google Scholar
• Murray KS, Ehdaie B, Musser J, et al. Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer. J Urol. 2016;196(3):883–890.
   PubMed Web of Science ®Google Scholar
• Valerio M, Dickinson L, Ali A, et al. Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer. J Urol. 2017;197(3 Pt 1):647–654.
   PubMed Web of Science ®Google Scholar
• Scheltema MJ, van den Bos W, de Bruin DM, et al. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial. BMC Cancer. 2016;16:299.
   PubMed Web of Science ®Google Scholar
• Vakrat-Haglili Y, Weiner L, Brumfeld V, et al. The microenvironment effect on the generation of reactive oxygen species by Pd-bacteriopheophorbide. J Am Chem Soc. 2005;127(17):6487–6497.
   PubMed Web of Science ®Google Scholar
• Azzouzi AR, Barret E, Bennet J, et al. TOOKAD(R) soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol. 2015;33(7):945–953.
   PubMed Web of Science ®Google Scholar
• Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(2):181–191.
   PubMed Web of Science ®Google Scholar
• Stern JM, Kibanov Solomonov VV, Sazykina E, et al. Initial evaluation of the safety of nanoshell-directed photothermal therapy in the treatment of prostate disease. Int J Toxicol. 2016;35(1):38–46.
   PubMed Web of Science ®Google Scholar
• Shanmugabavan Y, Bass E, Hulme A, et al. 758 - Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: an open label, phase 2a study. Eur Urol Supplements. 2017;16(3):e1308–e9.
   Google Scholar
• Tay KJ, Villers A, Polascik TJ. Targeted anterior gland focal therapy-a novel treatment option for a better defined disease. Curr Urol Rep. 2016;17(10):69.
   PubMed Web of Science ®Google Scholar
• Sivaraman A, Barret E. Focal therapy for prostate cancer: an “A la Carte” approach. Eur Urol. 2016;69(6):973–975.
   PubMed Web of Science ®Google Scholar
• Demanes DJ, Martinez AA, Ghilezan M, et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81(5):1286–1292.
   PubMed Web of Science ®Google Scholar
• Aluwini S, Van Rooij P, Hoogeman M, et al. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol. 2013;8:84.
   PubMed Web of Science ®Google Scholar
• Kim K, Zhang H, LaRosa S, et al. Bombesin antagonist based radiotherapy of prostate cancer combined with WST-11 vascular targeted photodynamic therapy. Clin Cancer Res. 2017.
   Web of Science ®Google Scholar
• Han B, Bischof JC. Direct cell injury associated with eutectic crystallization during freezing. Cryobiology. 2004;48(1):8–21.
   PubMed Web of Science ®Google Scholar
• Baust JG, Bischof JC, Jiang-Hughes S, et al. Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer Prostatic Dis. 2015;18:87–95.
   PubMed Web of Science ®Google Scholar
• Jiang J, Goel R, Iftekhar MA, et al. Tumor necrosis factor-alpha-induced accentuation in cryoinjury: mechanisms in vitro and in vivo. Mol Cancer Ther. 2008;7(8):2547–2555.
   PubMed Web of Science ®Google Scholar
• Santucci KL, Snyder KK, Baust JM, et al. Use of 1,25alpha dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer Prostatic Dis. 2011;14(2):97–104.
   PubMed Web of Science ®Google Scholar
• Walsh PC. 2008 Whitmore Lecture: radical prostatectomy – where we were and where we are going. Urol Oncol: Seminars and Original Investigations. 2009;27(3):246–250.
   PubMed Web of Science ®Google Scholar
• Masterson TA, Cheng L, Koch MO. Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens. BJU Int. 2011;107(10):1587–1591.
   PubMed Web of Science ®Google Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.
   PubMed Web of Science ®Google Scholar
• Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–277.
   PubMed Web of Science ®Google Scholar